ArticleJournal of animal science2025
Dietary L-glutamine supplementation enhances growth performance and carcass characteristics in Hanwoo heifers via hepatic and skeletal muscle gene regulation.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the important roles of L-glutamine (L-Gln) in protein synthesis and energy metabolism, we hypothesized that L-Gln supplementation could improve growth performance and carcass characteristics in Hanwoo heifers. This study aimed to investigate the effects of L-Gln supplementation on growth performance, carcass characteristics, and gene expression in the liver and skeletal muscle of Hanwoo heifers. A total of 44 Hanwoo heifers (age: 23.7 ± 0.7 mo; body weight [BW]: 458 ± 68 kg) were allocated to three dietary treatment groups using a randomized block design, with the experimental start date as the blocking factor. The dietary treatments included L-Gln supplementation through top dressing based on the dry matter feed at 0% (n = 13), 0.25% (n = 16), and 0.5% (n = 15). The treatment lasted for 195 d (6.5 mo), followed by slaughter. Hematological parameters, growth performance, carcass characteristics, and gene expression in the liver and skeletal muscle samples obtained from the carcass were evaluated. Statistical analyses were performed using the MIXED procedure of SAS 9.4, with L-Gln supplementation as a fixed effect and block as a random effect. The 0.25% L-Gln group showed a significant increase (P < 0.05) in final BW, carcass weight, ribeye area, and fat color compared with the 0% group. In the liver, the expression of glutaminase 2 (GLS2) was significantly decreased (P < 0.05) in both the 0.25% and 0.5% L-Gln groups. Furthermore, the 0.5% L-Gln group exhibited lower (P < 0.05) expression levels of pyruvate carboxylase (PC), phosphoenolpyruvate carboxykinase 1 (PCK1), and phosphoenolpyruvate carboxykinase 2 (PCK2). The expression of glucose-6-phosphatase catalytic subunit 1 (G6PC1) also decreased (P < 0.05) in the 0.25% L-Gln group. In the skeletal muscle, myogenic differentiation 1 (MYOD) expression was significantly higher in the 0.25% L-Gln group, while the 0.5% L-Gln group showed higher zinc finger protein 423 (ZNF423) expression (P < 0.05). Additionally, the expression levels of myogenin (MYOG), heat shock protein beta-1 (HSPB1), CCAAT enhancer binding protein alpha (CEBPA), and fatty acid binding protein 4 (FABP4) were increased (P < 0.05) in both the 0.25% and 0.5% L-Gln groups. Overall, dietary supplementation with 0.25% L-Gln improved the final BW, carcass weight, and ribeye area in fattening Hanwoo heifers, which is possibly related to the regulation of myogenic genes, HSPB1, and enzymes involved in hepatic Gln metabolism and gluconeogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.